Discontinuation of pessary therapy within 24 months: can it be predicted?
- PMID: 39614906
- DOI: 10.1007/s00404-024-07846-y
Discontinuation of pessary therapy within 24 months: can it be predicted?
Abstract
Introduction: Pelvic organ prolapse is a distressing condition affecting women. Pessary therapy is a conservative and effective treatment option. However, 20-60% of women discontinue pessary treatment within 24 months.
Objective: To identify patient characteristics associated with discontinuation of pessary treatment for symptomatic pelvic organ prolapse up to 24 months and to explore whether a prediction model can be developed.
Study design: Prospective observational study in 22 Dutch hospitals with a follow-up duration of 24 months.
Method: Baseline patient characteristics from 6 different domains were compared between women who continued pessary therapy and women who discontinued pessary therapy within 24 months. Women with initial fitting failure were not included in analysis. Univariable and multivariable analysis were applied to identify predictors.
Results: Of the 251 women included in analysis, 102 stopped using a pessary at 24 months (40.6%). After multivariable analysis, age (OR 0.95, 95% CI 0.92-0.98, p < 0.001) and the presence of patient-reported allergies (OR 2.48, 95% CI 1.32-4.66, p = 0.005) were found to be predictive for pessary discontinuation within 24 months. These two factors explain 11% of the models' variance. However, in 49% of patient-reported allergies, the allergy was not specified.
Conclusion: Younger women and those who reported allergies at baseline were less likely to continue pessary use. However, the high number of unspecified reported allergies and the lack of a clear scientific explanation, suggests that a direct causal link is unlikely and warrants additional research.
Keywords: Conservative treatment; Multivariable analysis; Patient characteristics; Pelvic organ prolapse; Predictors.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors have no financial or non-financial interests to disclose. Ethical approval: This study was approved by the Medical Research Ethics Committee (MREC), or Medisch Ethische Toetsing Commissie (METC), in Dutch. The date of approval was 22 September 2015 and the METC protocol number is 14-533/M.
References
-
- Bugge C, Adams EJ, Gopinath D, Stewart F, Dembinsky M, Sobiesuo P, Kearney R (2020) Pessaries (mechanical devices) for managing pelvic organ prolapse in women. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD004010.pub4 - DOI - PubMed - PMC
-
- van der Vaart L, Vollebregt A, Milani A, Lagro-Janssen A, Duijnhoven R, Roovers J, Van der Vaart C (2022) Pessary or surgery for a symptomatic pelvic organ prolapse: the PEOPLE study, a multicentre prospective cohort study. BJOG 129:820–829. https://doi.org/10.1111/1471-0528.16950 - DOI - PubMed
-
- Abdool Z, Thakar R, Sultan AH, Oliver RS (2011) Prospective evaluation of outcome of vaginal pessaries versus surgery in women with symptomatic pelvic organ prolapse. Int Urogynecol J 22:273–278. https://doi.org/10.1007/s00192-010-1340-9 - DOI - PubMed
-
- van der Vaart LR, Vollebregt A, Milani AL, Lagro-Janssen AL, Duijnhoven RG, Roovers J-PWR, van der Vaart CH (2022) Effect of pessary vs surgery on patient-reported improvement in patients with symptomatic pelvic organ prolapse. JAMA 328:2312. https://doi.org/10.1001/jama.2022.22385 - DOI - PubMed - PMC
-
- Mao M, Xu T, Kang J, Zhang Y, Ai F, Zhou Y, Zhu L (2019) Factors associated with long-term pessary use in women with symptomatic pelvic organ prolapse. Climacteric 22:478–482. https://doi.org/10.1080/13697137.2019.1582623 - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical